MA33517B1 - Analogues acylés du glucagon - Google Patents

Analogues acylés du glucagon

Info

Publication number
MA33517B1
MA33517B1 MA34615A MA34615A MA33517B1 MA 33517 B1 MA33517 B1 MA 33517B1 MA 34615 A MA34615 A MA 34615A MA 34615 A MA34615 A MA 34615A MA 33517 B1 MA33517 B1 MA 33517B1
Authority
MA
Morocco
Prior art keywords
glucagon
acel
methods
relates
peptides
Prior art date
Application number
MA34615A
Other languages
Arabic (ar)
English (en)
Inventor
Ditte Riber
Eddi Meier
Jens Rosengren Daugaard
Marie Skovgaard
Jakob Lind Tolborg
Gita Kampen
Camilla Ærteberg Bæk
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MA33517B1 publication Critical patent/MA33517B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des matériaux et sur des procédés pour favoriser la perte de poids ou pour prévenir la prise de poids, et pour traiter le diabète et les troubles métaboliques associés. En particulier, l'invention porte sur de nouveaux peptides analogues acylés du glucagon efficaces dans le cadre desdits procédés. Les peptides peuvent médier leur effet en ayant une sélectivité accrue pour le récepteur GLP-1 par comparaison au glucagon humain.
MA34615A 2009-07-13 2012-02-08 Analogues acylés du glucagon MA33517B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22508009P 2009-07-13 2009-07-13
EP09251780 2009-07-13
EP10157240 2010-03-22
DKPA201000412 2010-05-10
PCT/DK2010/000099 WO2011006497A1 (fr) 2009-07-13 2010-06-24 Analogues acylés du glucagon

Publications (1)

Publication Number Publication Date
MA33517B1 true MA33517B1 (fr) 2012-08-01

Family

ID=43448959

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34615A MA33517B1 (fr) 2009-07-13 2012-02-08 Analogues acylés du glucagon

Country Status (29)

Country Link
US (3) US9156901B2 (fr)
EP (1) EP2454282B1 (fr)
JP (1) JP6054742B2 (fr)
KR (1) KR101809024B1 (fr)
CN (2) CN104961822A (fr)
AP (1) AP3329A (fr)
AU (1) AU2010272944B2 (fr)
CA (1) CA2767792A1 (fr)
DK (1) DK2454282T3 (fr)
EA (1) EA022816B1 (fr)
EC (1) ECSP12011593A (fr)
ES (1) ES2537287T3 (fr)
GE (1) GEP20146056B (fr)
HR (1) HRP20150557T1 (fr)
HU (1) HUE026255T2 (fr)
IL (1) IL217150A0 (fr)
MA (1) MA33517B1 (fr)
ME (1) ME02220B (fr)
MX (1) MX2012000564A (fr)
MY (1) MY188182A (fr)
NZ (1) NZ597981A (fr)
PE (1) PE20121130A1 (fr)
PL (1) PL2454282T3 (fr)
PT (1) PT2454282E (fr)
RS (1) RS53987B1 (fr)
SG (1) SG177609A1 (fr)
SI (1) SI2454282T1 (fr)
UA (1) UA104766C2 (fr)
WO (1) WO2011006497A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370462B1 (fr) 2008-12-15 2014-07-16 Zealand Pharma A/S Analogues du glucagon
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) * 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
KR20140043709A (ko) * 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
WO2012153196A2 (fr) 2011-05-10 2012-11-15 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
UA126465C2 (uk) * 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
IN2014CN04401A (fr) * 2011-12-23 2015-09-04 Zealand Pharma As
IN2014MN02304A (fr) 2012-05-03 2015-08-07 Zealand Pharma As
EP2664374A1 (fr) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Dérivés de dipeptide d'acide lysine-glutamique
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
IN2015DN00544A (fr) 2012-07-23 2015-06-26 Zealand Pharma As
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014073842A1 (fr) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Formulation liquide d'un conjugué protéique comprenant l'oxyntomoduline et un fragment d'immunoglobuline
MX360816B (es) 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CA2902352A1 (fr) * 2013-03-14 2014-09-18 Medimmune Limited Co-agonistes pegyles du glucagon et de glp-1 pour le traitement de l'obesite
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CA2907454C (fr) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthese de produits peptidiques contenant de l'hydantoine
WO2014161835A1 (fr) 2013-04-03 2014-10-09 Sanofi Protéines de régulation de la glycémie modifiées ayant un profil d'activité pharmacologique modifié, et leur préparation
EP2986313B1 (fr) 2013-04-18 2019-06-12 Novo Nordisk A/S Co-agonistes stables de récepteur de glucagon/glp1 à effet prolongé
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (fr) * 2013-11-06 2015-05-14 Zealand Pharma A/S Composés agonistes doubles de gip et glp-1 et procédés associés
WO2015086728A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
WO2015086733A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
MX2016010599A (es) 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
PT3155017T (pt) 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN104926934B (zh) * 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
WO2016168388A2 (fr) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Thérapies pour l'obésité, le diabète et indications associées
DK3283507T3 (da) * 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
WO2016198628A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
EP4523705A3 (fr) 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
ES2983409T3 (es) * 2016-03-10 2024-10-23 Medimmune Ltd Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
CN105968186B (zh) * 2016-06-02 2020-10-30 中国药科大学 具有长效化作用的胰高血糖素(Glu)类似物及其应用
CN106084031B (zh) * 2016-06-02 2020-03-31 中国药科大学 一类glp-1r/gcgr双重激动剂在用于降糖和减肥药物中的运用
US11179444B2 (en) 2016-06-09 2021-11-23 Amidebio, Llc Glucagon analogs and methods of use thereof
EP3479841A4 (fr) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci
SG11201811804QA (en) 2016-08-05 2019-01-30 Boehringer Ingelheim Int Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
WO2018104558A1 (fr) * 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acylés
EP3551651B1 (fr) * 2016-12-09 2024-03-06 Zealand Pharma A/S Doubles agonistes glp-1/glp-2 acylés
CA3044915A1 (fr) * 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
WO2019149659A1 (fr) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
EP3746449B1 (fr) 2018-02-02 2022-03-30 Boehringer Ingelheim International GmbH Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat)
AU2019215707A1 (en) 2018-02-02 2020-07-09 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
CN110317258B (zh) * 2018-03-29 2023-03-17 齐鲁制药有限公司 一种索玛鲁肽的新多肽片段及其制备方法
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
MX2022006861A (es) 2019-12-04 2022-07-11 Scripps Research Inst Agonistas del receptor glp2 y metodos de uso.
CN115916789B (zh) 2020-05-22 2025-06-27 勃林格殷格翰国际有限公司 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
WO2021233882A1 (fr) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP0932614A1 (fr) 1996-09-09 1999-08-04 Zealand Pharmaceuticals A/S Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
JP4716641B2 (ja) 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1620465A2 (fr) 2003-04-29 2006-02-01 Eli Lilly And Company Analogues de l'insuline ayant une action prolongee
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2607566A1 (fr) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2913805A1 (fr) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
WO2007081824A2 (fr) 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
CA2638800A1 (fr) 2006-02-22 2007-09-07 Merck & Co., Inc. Derives d'oxyntomoduline
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
ITMI20061607A1 (it) 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
WO2008043033A2 (fr) 2006-10-04 2008-04-10 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CA2677932A1 (fr) * 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Co-agonistes des recepteurs du glucagon/glp-1
EP2025684A1 (fr) 2007-08-15 2009-02-18 Zealand Pharma A/S Analogues du glucagon
EP2158214B1 (fr) 2007-06-15 2011-08-17 Zealand Pharma A/S Analogues du glucagon
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
EP2296692A4 (fr) 2008-04-22 2012-06-06 Univ Case Western Reserve Analogues de l insuline spécifiques à l isoforme
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
MX2011001181A (es) 2008-07-31 2011-04-05 Univ Case Western Reserve Insulina estabilizada con halogeno.
WO2010016940A2 (fr) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2370462B1 (fr) 2008-12-15 2014-07-16 Zealand Pharma A/S Analogues du glucagon
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
US20100240883A1 (en) 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
EP2443146B1 (fr) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Composés de glucagon actifs sur le récepteur gip
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
AU2011247824B2 (en) 2010-04-27 2014-02-13 Betta Pharmaceuticals Co., Ltd Glucagon-like peptide-1 analogue and use thereof
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
WO2012153196A2 (fr) 2011-05-10 2012-11-15 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
IN2014CN04401A (fr) 2011-12-23 2015-09-04 Zealand Pharma As
IN2014MN02304A (fr) 2012-05-03 2015-08-07 Zealand Pharma As
IN2015DN00544A (fr) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067715A2 (fr) 2013-11-06 2015-05-14 Zealand Pharma A/S Composés agonistes doubles de gip et glp-1 et procédés associés
MX2016010599A (es) 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog

Also Published As

Publication number Publication date
KR101809024B1 (ko) 2017-12-14
EA022816B1 (ru) 2016-03-31
SI2454282T1 (sl) 2015-06-30
WO2011006497A1 (fr) 2011-01-20
AP3329A (en) 2015-06-30
CN102574903B (zh) 2015-07-08
US20190076506A1 (en) 2019-03-14
PE20121130A1 (es) 2012-08-30
EP2454282B1 (fr) 2015-03-04
GEP20146056B (en) 2014-03-10
PT2454282E (pt) 2015-06-23
JP6054742B2 (ja) 2016-12-27
PL2454282T3 (pl) 2015-08-31
AU2010272944B2 (en) 2015-11-19
EA201290027A1 (ru) 2013-01-30
IL217150A0 (en) 2012-02-29
ECSP12011593A (es) 2012-02-29
US20160120951A1 (en) 2016-05-05
CN104961822A (zh) 2015-10-07
AP2012006107A0 (en) 2012-02-29
MY188182A (en) 2021-11-24
US20120178670A1 (en) 2012-07-12
SG177609A1 (en) 2012-02-28
NZ597981A (en) 2014-02-28
ME02220B (me) 2016-02-20
ES2537287T3 (es) 2015-06-05
RS53987B1 (sr) 2015-10-30
HK1171035A1 (en) 2013-03-15
US10004786B2 (en) 2018-06-26
HRP20150557T1 (xx) 2015-07-03
DK2454282T3 (en) 2015-05-04
AU2010272944A1 (en) 2012-02-23
JP2012532898A (ja) 2012-12-20
HUE026255T2 (en) 2016-06-28
CA2767792A1 (fr) 2011-01-20
US9156901B2 (en) 2015-10-13
CN102574903A (zh) 2012-07-11
KR20120052973A (ko) 2012-05-24
EP2454282A1 (fr) 2012-05-23
UA104766C2 (uk) 2014-03-11
MX2012000564A (es) 2012-04-11

Similar Documents

Publication Publication Date Title
MA33517B1 (fr) Analogues acylés du glucagon
MA32970B1 (fr) Analogues du glucagon
MA34383B1 (fr) Analogues de glucagon
MA37983A1 (fr) Analogues du glucagon
NZ593813A (en) Glucagon analogues
MX2011006320A (es) Analogos de glucagon.
DK2158214T3 (da) Glukagonanaloger
EP3839049A3 (fr) Anticorps, domaines variables&chaînes adaptées pour une utilisation humaine
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
EP2500362A3 (fr) Anticorps humanisés contre TL1A
MA35864B1 (fr) Analogues du glucagon
WO2006074428A3 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
EP2388276A3 (fr) Anticorps humains à neutralisation anti-B7RP1
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EP4335863A3 (fr) Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP2062917A3 (fr) Anticorps du récepteurs de l'érythropoïétine et leurs utilisations
WO2008097428A3 (fr) Composés et compositions tels que des modulateurs d'une activité gpr119
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
WO2006091496A3 (fr) Potentialisateurs de benzazole de recepteurs de glutamate metabotropique
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
EP2604693A3 (fr) Molécules à chaîne unique TNFSF
WO2010009478A3 (fr) Compositions et procédés pour traiter des troubles associés à des animaux en surpoids
WO2008024302A8 (fr) Composés pour le traitement de troubles prolifératifs
EP3345925A3 (fr) Anticorps humanisés ciblant le domaine ec1 cadhérine-11 et compositions et procédés associés
WO2011044452A3 (fr) Procédés et compositions pour l'amélioration d'une maladie auto-immune utilisant des protéines de fusion d'un anticorps anti-récepteurs des cellules dendritiques avec des séquences peptidiques